3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Unknown
1
Terminated
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Solid Tumor, Adult
1
Pyloric Stenosis, Hypertrophic
1
Nasopharyngeal Carcinoma
1
Lymphoproliferative Disorders
1
Epstein-Barr Virus Infections
1
EBV Lymphomas
1
Advanced Cancer
1
Interventions
Rituximab
2
pembrolizumab
1
merphos
1
avelumab
1
apatinib
1
Zidovudine
1
Valganciclovir
1
Tegafur
1
Mitomycin
1
Methotrexate
1
Leucovorin
1
Hydroxyurea
1
Epirubicin
1
Doxorubicin
1
Cisplatin
1
Brentuximab Vedotin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Epstein-Barr Virus Infections
×
Valganciclovir
×
Clear all
NCT05011058
2025-07-28
NAVAL-1
Viracta Therapeutics, Inc.
Phase 2
Terminated
102 enrolled
28 charts